Current Methods for Surfactant Administration in Premature Infants with Respiratory Distress Syndrome

Öz

The survival rate of premature infants has increased dramatically, after the beginning of surfactant use in newborn clinics for premature infants with respiratory distress syndrome. The surfactant delivery methods to the lungs have started to evolve into less invasive and even non-invasive methods over the time. Studies on new methods such as thin catheter surfactant administration, laryngeal or supraglottic airway device, pharyngeal instillation, and aerosolized techniques are increasing. The purpose of the less invasive or noninvasive methods is the protection of immature lungs from harmful effects of intubation, positive pressure ventilation and invasive mechanical ventilation. It has been reported in many studies and meta-analysis that TCA methods were related to lower need of mechanical ventilation, shorter duration of mechanical ventilation, and lower incidence of bronchopulmonary dysplasia or death, compared to intubation, surfactant, and positive pressure ventilation methods. However, there are heterogeneities in premedication policies and respiratory support type, and the type of surfactant applied in the studies. Laryngeal or supraglottic airway device, pharyngeal instillation, and aerosolized techniques have advantages over thin catheter, because they eliminate the disadvantages of laryngoscopy, they are less invasive than thin catheter and they require minimal experience and skills, but more data are needed for routine clinical use of these new methods.

Anahtar Kelimeler

• Surfactant
• thin catheter surfactant administration
• laryngeal mask
• aerosol
• pharyngeal instillation.

RESPİRATUVAR DİSTRES SENDROMLU PREMATÜRE BEBEKLERDE SURFAKTAN UYGULANMASINDA GÜNCEL METOTLAR

Öz

Prematürelerde görülen respiratuvar distres sendromunda surfaktanın klinik kullanıma girmesi ile birlikte prematüre bebeklerdeki yaşam oranı dramatik olarak artmıştır. Surfaktanın akciğerlere iletiminde kullanılan yöntemler zaman içerisinde daha az invaziv ve hatta invaziv olmayan yöntemlere doğru evrilmeye başlamıştır. Surfaktanın ince kateter ile uygulanması, bir larengeal veya suproglottik havayolu cihazı kullanılarak, farengeal uygulama ile ve aerosolize şekilde verilmesi gibi yeni yöntem çalışmaları giderek artmaktadır. Böylece, immatür akciğerin klasik olarak kabul edilen entübasyon, pozitif basınçlı ventilasyon ve mekanik ventilasyonun zararlı etkilerinden korunması hedeflenmiştir. İnce kateter ile surfaktan uygulanması metodu ile yapılan çok sayıda çalışma ve meta-analizin sonuçları entübasyon, surfaktan uygulanması ve pozitif basınçlı ventilasyon metotları ile karşılaştırıldığında mekanik ventilasyon ihtiyacı ve süresi, bronkopulmoner displazi insidansı ve neonatal mortalite oranlarında azalmaya neden olduğu gösterilmiştir. Ancak çalışmalarda premedikasyon yönetimi ve solunum desteği türü, uygulanan surfaktan türü gibi birçok konuda heterojenite mevcuttur. Supraglottik hava yolu cihazı, farengeal uygulama ve aerosolizasyon uygulamaları özellikle laringoskopinin dezavantajlarını ortadan kaldırması ve daha da az invaziv olmaları, daha az tecrübe ve yetenek gerektirmeleri nedenleri ile ince kateter ile surfaktan uygulanması yönteminden avantajlı olsalar da henüz rutin klinik kullanıma girmeleri için daha fazla veriye ihtiyaç vardır.

Anahtar Kelimeler

• Surfaktan
• ince kateter surfaktan uygulama
• larengeal maske
• aerosol
• farengeal uygulama

Kaynakça

1. Jobe AH, Mitchell BR, Gunkel JH. Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant in preterm infants. Am J Obstet Gynecol. 1993;168(2):508-13.
2. Gregory G, Kitterman J, Phibbs R, Tooley W, Hamilton W. Treatment of the idiopathic respiratory-distress syndrome with continuous positive airway pressure. N Engl J Med. 1971;284:1333-40.
3. Blencowe H, Vos T, Lee AC, Philips R, Lozano R, Alvarado MR et al. Estimates of neonatal morbidities and disabilities at regional and global levels for 2010: introduction, methods overview, and relevant findings from the Global Burden of Disease study. Pediatr Res. 2013;74:4-16.
4. Panza R, Laforgia N, Bellos I, Pandita A. Systematic review found that using thin catheters to deliver surfactant to preterm neonates was associated with reduced bronchopulmonary dysplasia and mechanical ventilation. Acta Paediatr. 2020;109(11):2219-25.
5. Sakonidou, S. & Dhaliwal, J. The management of neonatal respiratory distress syndrome in preterm infants (European Consensus Guidelines-2013 update). Arch Dis Child Educ Pract Ed. 2015;100:257-9.
6. Verder H, Robertson B, Greisen G, Ebbesen F, Albertsen P, Lundstrøm K et al. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. Danish-Swedish Multicenter Study Group. N Engl J Med. 1994;331(16):1051-5.
7. Bohlin K, Gudmundsdottir T, Katz-Salamon M, Jonsson B, Blennow M. Implementation of surfactant treatment during continuous positive airway pressure. J Perinatol. 2007; 27:422-7.
8. Liechty EA, Donovan E, Purohit D, Gilhooley J, Feldman B, Noguchi A et al: Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome. Pediatrics. 1991;88:19-28.

9. Halliday H, Speer CP. Strategies for surfactant therapy in established neonatal respiratory syndrome. in Robertson B, Taeusch HW (eds). Surfactant Therapy for Lung Disease. New York, Marcel Dekker, 1995;443-54.
10. Soll RF, Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2001;2:CD000510.
11. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723-29.
12. Carlo WA. Gentle ventilation: the new evidence from the SUPPORT, COIN, VON, CURPAP, Colombian Network, and Neocosur Network trials. Early Hum Dev. 2012;88(Suppl 2):S81-3.
13. Göpel W, Kribs A, Härtel C, Avenarius S, Teig N, Groneck P et al. Less invasive surfactant administration is associated with improved pulmonary outcomes in spontaneously breathing preterm infants. Acta Paediatr. 2015;104:241-6.
14. Härtel C, Glaser K, Speer CP. The Miracles of Surfactant: Less Invasive Surfactant Administration, Nebulization, and Carrier of Topical Drugs. Neonatology. 2021;118(2):225-34.
15. Göpel W, Kribs A, Ziegler A, Laux R, Hoehn T, Wieg C et al. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet. 2011;378(9803):1627-34.
16. Kribs A, Roll C, Göpel W, Wieg C, Groneck P, Laux R et al. Nonintubated surfactant application vs conventional therapy in extremely preterm infants: a randomized clinical trial. JAMA Pediatr. 2015;169(8):723-30.
17. Guthrie SO, Fort P, Roberts KD. Surfactant Administration Through Laryngeal or Supraglottic Airways. Neoreviews. 2021;22(10):673-88.
18. Gaertner VD, Thomann J, Bassler D, Rüegger CM. Surfactant Nebulization to Prevent Intubation in Preterm Infants: A Systematic Review and Meta-analysis. Pediatrics. 2021;148(5):e2021052504.
19. Verder H, Agertoft L, Albertsen P, Christensen NC, Curstedt T, Ebbesen F et al. Surfactant treatment of newborn infants with respiratory distress syndrome primarily treated with nasal continuous positive air pressure. A pilot study Ugeskr Laeger. 1992;27:154(31):2136-9.
20. Kribs A, Pillekamp F, Hünseler C, Vierzig A, Roth B. Early administration of surfactant in spontaneous breathing with nCPAP: feasibility and outcome in extremely prematüre infants postmenstrual age
21. Kanmaz HG, Erdeve O, Canpolat FE, Mutlu B, Dilmen U. Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. Pediatrics. 2013;131(2):e502-9.
22. Dargaville PA, Aiyappan A, De Paoli AG, Kuschel CA, Kamlin OF, Carlin JB et al. Minimally‐invasive surfactant therapy in preterm infants on continuous positive airway pressure. Arch Dis Child Fetal Neonatal Ed. 2013;98:122‐6.
23. Abdel-Latif ME, Davis PG, Wheeler KI, De Paoli AG, Dargaville PA. Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome. Cochrane Database Syst Rev. 2021;10;5(5):CD011672.
24. De Luca D, Shankar-Aguilera S, Centorrino R, Fortas F, Yousef N, Carnielli VP. Less invasive surfactant administration: a word of caution. Lancet Child Adolesc Health. 2020;4(4):331-40.
25. Jourdain G, De Tersant M, Dell’Orto V, Conti G, De Luca D. Continuous positive airway pressure delivery during less invasive surfactant administration: a physiologic study. J Perinatol. 2018;38:271-77.
26. Devi U, Pandita A. Surfactant delivery via thin catheters: Methods, limitations, and outcomes. Pediatr Pulmonol. 2021;56(10):3126-41.
27. Mehler K, Broer A, Roll C, Göpel W, Wieg C, Jahn P et al. Developmental outcome of extremely preterm infants is improved after less invasive surfactant application: developmental outcome after LISA. Acta Paediatr. 2021;110:818‐25.
28. Teig N, Weitkämper A, Rothermel J, Bigge N, Lilienthal E, Rossler L et al. Observational Study on less invasive surfactant administration (LISA) in preterm infants <29 weeks—short and long‐term outcomes. Z Geburtshilfe Neonatol. 2015;219:266‐73.
29. Márquez Isidro E, Sánchez Luna M, Ramos‐Navarro C. Long‐term outcomes of preterm infants treated with less invasive surfactant technique (LISA). J Matern Fetal Neonatal Med. 2019;34:1‐6.
30. Porath M, Korp L, Wendrich D, Dlugay V, Roth B, Kribs A. Surfactant in spontaneous breathing with nCPAP: neurodevelopmental outcome at early school age of infants ≤27 weeks. Acta Paediatr. 2011;100:352‐9.
31. Olivier F, Nadeau S, Bélanger S, Julien AS, Massé E, Ali N et al. Efficacy of minimally invasive surfactant therapy in moderate and late preterm infants: a multicenter randomized control trial. Paediatr Child Health. 2017;22:120‐4.
32. Dargaville PA, Ali SKM, Jackson HD, Williams C, De, Paoli AG. Impact of minimally invasive surfactant therapy in preterm infants at 29‐32 weeks gestation. Neonatology. 2018;113:7‐14.
33. Seo MY, Shim GH, Chey MJ. Clinical Outcomes of Minimally Invasive Surfactant Therapy via Tracheal Catheterization in Neonates with a Gestational Age of 30 Weeks or More Diagnosed with Respiratory Distress Syndrome. Neonatal Medicine. 2018;25:109‐17.
34. Devi U, Roberts KD, Pandita A. A systematic review of surfactant delivery via laryngeal mask airway, pharyngeal instillation, and aerosolization: Methods, limitations, and outcomes. Pediatr Pulmonol. 2022;57(1):9-19.
35. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R et al; European Association of Perinatal Medicine. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants--2013 update. Neonatology. 2013;103(4):353-68.
36. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2016 Update. Neonatology. 2017;111(2):107-25.
37. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Te Pas A et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2019 Update. Neonatology. 2019;115(4):432-50.
38. Özkan H, Erdeve Ö, Kutman HGK. Turkish Neonatal Society guideline on the management of respiratory distress syndrome and surfactant treatment. Turk Pediatr Ars. 2018;53(suppl1):45-54.
39. Öncel MY, Erdeve Ö. A national survey on use of less invasive surfactant administration in Turkey. Turk J Pediatr. 2020;62(5):787-94.
40. Al Ali RA, Gautam B, Miller MR, Coulson S, Yuen D. Laryngeal mask airway for surfactant administration versus standard treatment methods in preterm neonates with respiratory distress syndrome: a systematic review and meta-analysis. Am J Perinatol. 2022;39(13):1433-40.
41. Pinheiro JMB, Santana‐Rivas Q, Pezzano C. Randomized trial of laryngeal mask airway versus endotracheal intubation for surfactant delivery. J Perinatol. 2016;36:196‐201.
42. Gallup JA, Pinheiro JM, Ndakor SM, Pezzano C. Randomized trial of surfactant therapy via laryngeal mask airway vs. brief tracheal intubation. Pediatrics. 2021;147:755‐6.
43. Attridge JT, Stewart C, Stukenborg GJ, Kattwinkel J. Administration of rescue surfactant by laryngeal mask airway: lessons from a pilot trial. Am J Perinatol. 2013;30:201‐6.
44. Sadeghnia A, Tanhaei M, Mohammadizadeh M, Nemati M. A comparison of surfactant administration through i‐gel and ET‐tube in the treatment of respiratory distress syndrome in newborns weighing more than 2000 grams. Adv Biomed Res. 2014;3:160.
45. Barbosa RF, Simões E, Silva AC, Silva YP. A randomized controlled trial of the laryngeal mask airway for surfactant administration in neonates. J Pediatr. 2017;93:343‐50.
46. Roberts KD, Brown R, Lampland AL, Leone TA, Rudser KD, Finer NN et al. Laryngeal mask airway for surfactant administration in neonates: a randomized, controlled trial. J Pediatr. 2018;193(40‐46):40‐6.
47. Amini E, Sheikh M, Shariat M, Dalili H, Azadi N, Nourollahi S. Surfactant administration in preterm neonates using laryngeal mask airway: a randomized clinical trial. Acta Med Iranica. 2019:348‐354.
48. Erdeve Ö, Okulu E, Roberts KD, Guthrie SO, Fort P, Kanmaz Kutman HG et al. Alternative methods of surfactant administration in preterm infants with respiratory distress syndrome: State of the art. Turk Arch Pediatr. 2021;56(6):553-62.
49. Vannozzi I, Ciantelli M, Moscuzza F, Scaramuzzo RT, Panizza D, Sigali E et al. Catheter and laryngeal mask endotracheal surfactant therapy: the CALMEST approach as a novel MIST technique. J Matern Fetal Neonatal Med. 2017;30:2375‐7.
50. Kattwinkel J, Robinson M, Bloom BT, Delmore P, Ferguson JE. Technique for intrapartum administration of surfactant without requirement for an endotracheal tube. J Perinatol. 2004;24:360‐5.
51. Ten Centre Study Group. Ten centre trial of artificial surfactant (artificial lung expanding compound) in very premature babies. Br Med J (Clin Res Ed). 1987;294:991‐6.
52. Lamberska T, Settelmayerova E, Smisek J, Luskova M, Maloskova G, Plavka R et al. Oropharyngeal surfactant can improve initial stabilisation and reduce rescue intubation in infants born below 25 weeks of gestation. Acta Paediatr. 2018;107(1):73-8.
53. Bianco F, Salomone F, Milesi I, Murgia X, Bonelli S, Pasini E et al. Aerosol drug delivery to spontaneously-breathing preterm neonates: lessons learned. Respir Res. 2021;22(1):71.
54. Minocchieri S, Berry CA, Pillow JJ. CureNeb Study Team. Nebulised surfactant to reduce severity of respiratory distress: a blinded, parallel, randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2019;104:313‐9.
55. Finer NN, Merritt TA, Bernstein G, Job L, Mazela J, Segal R. An open label, pilot study of Aerosurf® combined with nCPAP to prevent RDS in preterm neonates. J Aerosol Med Pulm Drug Deliv. 2010;23:303‐9.
56. Berggren E, Liljedahl M, Winbladh B, Andreasson B, Curstedt T, Robertson B et al. Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Paediatr. 2000;89:460‐4.
57. Cummings JJ, Gerday E, Minton S, Katheria A, Albert G, Flores-Torres J et al. Aerosolized calfactant for newborns with respiratory distress: a randomized trial. Pediatrics. 2020;146:146.
58. Sood BG, Cortez J, Kolli M, Sharma A, Delaney‐Black V, Chen X. Aerosolized surfactant in neonatal respiratory distress syndrome: phase I study. Early Hum Dev. 2019;134:19‐25.
59. Nord A, Bianco F, Salomone F, Ricci F, Schlun M, Linner R et al. Nebulization of high‐dose poractant alfa in newborn piglets on nasal continuous positive airway pressure yields therapeutic lung doses of phospholipids. Am J Perinatol. 2022;39(9):1001-7.
60. Silahli M, Tekin M. The Comparison of LISA and INSURE techniques in term of neonatal morbidities and mortality among premature infants. Acta Biomed. 2020;91(4):e2020189.